Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

73.95EUR
11:37am EDT
Change (% chg)

€-0.39 (-0.52%)
Prev Close
€74.34
Open
€74.29
Day's High
€74.34
Day's Low
€73.46
Volume
2,484,630
Avg. Vol
2,337,414
52-wk High
€80.44
52-wk Low
€64.45

Select another date:

FDA approves expanded label for Regeneron/Sanofi's cholesterol drug

The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.

UPDATE 1-U.S. FDA approves expanded label for Regeneron/Sanofi's cholesterol drug

April 26 The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.

Genzyme and vaccines push up Sanofi's first quarter results

PARIS Sanofi upheld a long-awaited return to growth on Friday with higher profits and revenues for the first quarter, once again led by a stellar sales increase at its rare diseases Genzyme unit.

UPDATE 1-Genzyme and vaccines push up Sanofi's Q1 results

* Pressure remains on diabetes and cardiovascular (Adds details)

Genzyme and vaccines push up Sanofi's Q1 results

PARIS, April 26 Sanofi upheld a long-awaited return to growth on Friday with higher profits and revenues for the first quarter, once again led by a stellar 31 percent sales increase at its rare diseases Genzyme unit.

Sanofi to cut U.S. insulin costs for some patients to $99 per month

NEW YORK Sanofi SA said on Wednesday it will cut the cost of its insulin products to $99 per month for uninsured patients and others who pay cash for it in the United States, as the French drugmaker contends with intense criticism over the high price of the life-sustaining diabetes medication.

Sanofi to cut U.S. insulin costs for some patients to $99 per month

NEW YORK, April 10 Sanofi SA said on Wednesday it will cut the cost of its insulin products to $99 per month for uninsured patients and others who pay cash for it in the United States, as the French drugmaker contends with intense criticism over the high price of the life-sustaining diabetes medication.

FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes

The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc intended for use with insulin in patients with type 1 diabetes, the companies said on Friday.

UPDATE 1-FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes

March 22 The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc intended for use with insulin in patients with type 1 diabetes, the companies said on Friday.

Select another date: